Announced Sat, 6 Jun · 20:43 IST

Further to the intimation letter dated August 02, 2025, we hereby inform that the Companyhas completed an additional investment of ₹ 2.5 million in the wholly owned subsidiaryof the Company Advanced Nutrazyme Private Limited [ ANPL ] by way of investing inthe rights issue of 2,50,000 Equity Shares of ₹ 10 each. With this, the investment of theCompany in ANPL has increased to ₹3 million divided into 3,00,000 Equity Shares of ₹10each.

Strategic Transactions View source PDF

ADVENZYMES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.7%1-day move
₹367.00
prior close
₹360.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+2.8+2.6+2.4+2.7+1.7+0.8-1.2+1.1+0.3+1.8-16.1-13.1
Up moveDown movePending
AI summary

Advanced Enzyme Technologies has completed an additional investment of ₹2.5 million in its wholly owned subsidiary Advanced Nutrazyme Private Limited (ANPL) by subscribing to a rights issue of 2,50,000 equity shares of ₹10 each. With this fresh infusion, the company's total investment in ANPL now stands at ₹3 million, spread across 3,00,000 equity shares of ₹10 each. ANPL remains a wholly owned subsidiary, and the investment appears to be a routine capital infusion to fund the subsidiary's operations or growth. This follows an earlier intimation dated August 02, 2025.

Likely market impact

This is a small, routine capital infusion into a wholly owned subsidiary and is unlikely to have a material impact on the parent company's stock price or shareholder value in the near term.